WSE

EQS-News: Photon Energy Signs O&M Contract for 100 MWp Rutki and Góra PV Power Plants

Retrieved on: 
Thursday, December 14, 2023
Photon, Nominal power (photovoltaic), OX2, Acceleration, Czech Republic, WSE, Growth, Plant, PV, CEE, FSX, O&M, Photon energy, Renewable energy, Rutki

Photon Energy has signed a full operations and maintenance (O&M) contract for 100.19 MWp installed PV generation capacity with OX2 Construction AB (‘OX2’), one of Europe’s leading developers of renewable energy sources, headquartered in Sweden.

Key Points: 
  • Photon Energy has signed a full operations and maintenance (O&M) contract for 100.19 MWp installed PV generation capacity with OX2 Construction AB (‘OX2’), one of Europe’s leading developers of renewable energy sources, headquartered in Sweden.
  • The Company has concluded O&M service contracts for a combined 267.5 MWp of PV assets in the Polish market.
  • Amsterdam/Warsaw – 30 November 2023 – Photon Energy N.V. (WSE&PSE: PEN, FSX: A1T9KW) (‘Photon Energy Group’ or the ‘Company’) announces that its Polish solar O&M services subsidiary Photon Energy Operations PL Sp.
  • We are committed to ensuring that the Rutki and Góra power plants will have industry-leading uptime and performance,’ said Georg Hotar, CEO of Photon Energy Group.

BBSI Reports Strong Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
PEO, WSES, Growth, Marketing, WSE, Investment, Beauty salon, Clothing, Cryptocurrency, Video game, Communications satellite

VANCOUVER, Wash., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Barrett Business Services, Inc. (“BBSI” or the “Company”) (NASDAQ: BBSI), a leading provider of business management solutions, reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • - Q3 2023 Net Income of $18.2 Million, or $2.68 per Diluted Share -
    VANCOUVER, Wash., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Barrett Business Services, Inc. (“BBSI” or the “Company”) (NASDAQ: BBSI), a leading provider of business management solutions, reported financial results for the third quarter ended September 30, 2023.
  • “We continued to generate strong results from our expanding client base and on-going roll-out of BBSI Benefits,” said BBSI President and CEO, Gary Kramer.
  • We also continued to see positive results in our pricing and cost management strategies, resulting in strong, sustainable earnings growth.”
    Revenues in the third quarter of 2023 decreased 0.2% to $273.3 million compared to $273.8 million in the third quarter of 2022.
  • BBSI now expects the following for 2023:
    BBSI will conduct a conference call on Wednesday, November 1, 2023, at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to discuss its financial results for the quarter ended September 30, 2023.

Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120

Retrieved on: 
Monday, October 23, 2023
Medulloblastoma, Bone marrow, Plasma, AUC, Acute myeloid leukemia, Cmax, ESMO, Erythropoiesis, Principal investigator, Aes, PD, Congress, MD, Adenoid cystic carcinoma, CEST, Ruxolitinib, Cell, Data, Syndrome, All-comers track meet, Phase, SD, Risk, Webcast, Pancreatic cancer, Venetoclax, NPM1, WSE, ADCC, Safety, European Society for Medical Oncology, Patient, AML, Sarcoma, Pharmaceutical industry, Medical imaging, Dietary supplement

The total budget for the Phase II clinical development of RVU120 aligns with the estimates initially announced in the Ryvu Development Plans for 2022-2024.

Key Points: 
  • The total budget for the Phase II clinical development of RVU120 aligns with the estimates initially announced in the Ryvu Development Plans for 2022-2024.
  • The presented RVU120 development plan aligns with the budget outlined in Ryvu Development Plans for 2022-2024 and targets multi-billion-dollar market potential.
  • At the ESMO Congress 2023, Ryvu announced updated clinical Phase I data from Phase I/II study of RVU120 in relapsed/refractory metastatic advanced solid tumors.
  • Ryvu will host a webinar today (Monday, October 23) at 9:00 am CEST to discuss further RVU120 development plans.

Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Monday, October 16, 2023
Molecular mechanics, Step Forward, Pharmacokinetics, KRAS, Lymphoma, AACR, Cas9, Apoptosis, Mantle cell lymphoma, Colorectal cancer, PK, IND, PRMT5, Large intestine, RNA-Seq, CRC, WSE, CEST, Therapy, Phase, DLBCL, WRN, IC50, Drug discovery, PIM, MTA, Transcriptome, Conference, Vaccine, Pharmaceutical industry

"We are pleased with preclinical data underscoring the promise of our synthetic lethality platform, as highlighted by our leading preclinical program on PRMT5 inhibitors," said Krzysztof Brzózka, Ph.D., Chief Scientific Officer of Ryvu Therapeutics.

Key Points: 
  • "We are pleased with preclinical data underscoring the promise of our synthetic lethality platform, as highlighted by our leading preclinical program on PRMT5 inhibitors," said Krzysztof Brzózka, Ph.D., Chief Scientific Officer of Ryvu Therapeutics.
  • Our potentially best-in-class MTA-cooperative PRMT5 inhibitors exhibit significantly improved pharmacokinetics relative to other PRMT5 inhibitors currently in development.
  • Given their in vivo target engagement and remarkable anti-tumor efficacy, we anticipate further development and progression to IND-enabling studies in 2024.
  • Webinar on PRMT5 and synthetic lethality pipeline, including WRN project and target discovery efforts
    Ryvu will host a webinar today at 9:30 am CEST to discuss the PRMT5 data.

Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, October 4, 2023
MTAP, CRISPR, Intellectual property, AACR, B-cell lymphoma, CRC, Molecular mechanics, WSE, MTA, DLBCL, Neoplasm, RNA-Seq, Mantle cell lymphoma, Large intestine, Cell, Transcriptome, Colorectal cancer, Potent, Lymphoma, PIM, CEST, Apoptosis, Genetic distance, Step Forward, Therapy, Conference, PRMT5, Cryptocurrency, Pharmaceutical industry, Vaccine

“During this year's AACR-NCI-EORTC conference, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, representing the flagship initiative within Ryvu’s synthetic lethality platform.

Key Points: 
  • “During this year's AACR-NCI-EORTC conference, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, representing the flagship initiative within Ryvu’s synthetic lethality platform.
  • Details on the poster presentations are as follows:
    Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable properties and effective PRMT5 inhibition dependent on MTA.
  • Ryvu has developed a comprehensive platform using CRC model cells derived from human intestinal stem cells, patient-derived xenografts, and clinical samples.
  • Ryvu will host a webinar on Monday, October 16, at 9:30 am CEST to discuss the PRMT5 data.

Ryvu Therapeutics' Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)

Retrieved on: 
Thursday, September 14, 2023
Lymphoma, WSE, Non-Hodgkin lymphoma, Research, AML, Patient, IDH, Phase, Therapy, Pharmaceutical industry, DLBCL

KRAKÓW, Poland , Sept. 14, 2023 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced that Ryvu's licensee, the Menarini Group, will expand development of MEN1703 (SEL24) by initiating a new Phase II study in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in addition to continued translational work in other hematologic indications.

Key Points: 
  • "We are excited to begin this Phase II study with our partner Menarini to address the critical unmet need in DLBCL," said Pawel Przewiezlikowski, co-founder, largest shareholder, and CEO of Ryvu Therapeutics.
  • Based on these data, development of MEN1703 will continue with focus on DLBCL and potentially other indications.
  • Under the terms of the license agreement executed in 2017, Menarini is the global development and commercial licensee.
  • "We are pleased to advance MEN1703 into clinical development and look forward to exploring its therapeutic potential in DLBCL as well as evaluating it in other promising indications."

EQS-News: Photon Energy Joins RayGen to Open World-Leading Solar and Storage Plant in Australia

Retrieved on: 
Saturday, September 16, 2023
Photon, Partnership, Photon energy, Chevron Corporation, WSE, Schlumberger, Electricity, Australian Renewable Energy Agency, Investment, ARENA, AGL Energy, Solar energy, GWP, FSX, SLB, Renewable energy, Cryptocurrency

Photon Energy plans to deploy the unique RayGen technology for its 200 MW PV solar coupled with 115 MW of thermal storage project in Yadnarie, Australia.

Key Points: 
  • Photon Energy plans to deploy the unique RayGen technology for its 200 MW PV solar coupled with 115 MW of thermal storage project in Yadnarie, Australia.
  • Amsterdam/Sydney – 8 September 2023 – Photon Energy N.V. (WSE&PSE: PEN, FSX: A1T9KW) (‘Photon Energy Group’ or the ‘Company’), an Amsterdam-based renewable energy company delivering clean energy and water solutions in Europe and Australia joined with the Melbourne-based energy technology company RayGen Resources Pty Ltd (‘RayGen’) to celebrate the opening of RayGen’s innovative solar-plus-storage plant in Carwarp, Victoria.
  • ‘We are excited to celebrate the opening of RayGen’s solar-plus-storage plant, an important milestone in the energy transition in Australia and beyond’, said Georg Hotar, CEO of Photon Energy Group.
  • Along with developing RayGen projects, Photon Energy Group has since April 2020 made several equity investments in RayGen maintaining 7.6% stake in the high-tech company.

Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, September 13, 2023
Good manufacturing practice, Incentive program, WSE, Congress, QP, Patient, United States Commercial Service, SE, Disease, Warsaw Stock Exchange, Research, USD, European Hematology Association, International Conference on Afghanistan, London (2010), CGMP, Hematology, ADC, Phase, Conference, Venetoclax, Safety, BioNTech, WIG20, Exelixis, API, History, Fibrosis, Pancreatic serous cystadenoma, Contract research organization, MA, Therapy, Splenomegaly, Cost, EDC, Data management, Good, ABM, AML, EHA, Dietary supplement, Pharmaceutical industry, Cryptocurrency

Updated clinical and preclinical data on RVU120 were presented at the European Hematology Associated (EHA) Congress in June 2023.

Key Points: 
  • Updated clinical and preclinical data on RVU120 were presented at the European Hematology Associated (EHA) Congress in June 2023.
  • $14M in non-dilutive grant funding was secured from the Medical Research Agency (ABM) – the largest grant obtained to date by Ryvu.
  • KRAKOW, Poland, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, reported today financial results for the first half of 2023 and provided a corporate update.
  • “The last months of 2023 were a productive period for Ryvu as we made significant developments across our clinical programs, collaboration activity, and strengthening our balance sheet”, said Pawel Przewiezlikowski, CEO of Ryvu Therapeutics.

EQS-News: Photon Energy Connects 10.3 MWp Solar PV Power Plants to the Grid in Romania

Retrieved on: 
Wednesday, August 30, 2023
Photon, Maintenance, Photon energy, WSE, Independent power producer, Nominal power (photovoltaic), Power, Electricity, EPC, PV, Plant, EUR, Engineering, Kilowatt-hour, CEE, O&M, GWP, FSX, Electric battery, Renewable energy

Amsterdam/Bucharest – 30 August 2023 – Photon Energy N.V. (WSE&PSE: PEN, FSX: A1T9KW) (‘Photon Energy Group’ or the ‘Company’) announces that Photon Energy Engineering Romania S.R.L.

Key Points: 
  • Amsterdam/Bucharest – 30 August 2023 – Photon Energy N.V. (WSE&PSE: PEN, FSX: A1T9KW) (‘Photon Energy Group’ or the ‘Company’) announces that Photon Energy Engineering Romania S.R.L.
  • ‘We are excited to have expanded our portfolio of operating solar PV assets by an additional 10.3 MWp,’ said Georg Hotar, CEO of Photon Energy Group.
  • The power plants are owned and operated by special-purpose companies, which themselves are fully owned by Photon Energy Group.
  • The Company’s IPP (Independent Power Producer) portfolio now includes 96 solar power plants, with a combined generation capacity of 123.4 MWp.

EQS-News: Photon Energy Group Reports Financial and Operational Results for the First Half of 2023

Retrieved on: 
Tuesday, August 22, 2023
Photon, National Keelung Commercial & Industrial Vocational Senior High School, Operation, PFAS, WSE, Electricity, EPC, Operational maintenance, EBIT, Plant, DSR, EBITDA, IPP, Soil, Engineering, Groundwater, Growth, O&M, Yoy, Weather, Commercial, FSX, Ministry, Six Months in a Convent, Film industry, Lithium, Rare-earth element, Renewable energy, PV, EUR

Unaudited consolidated EBITDA dropped to EUR 2.833 million compared to EUR 10.142 million a year earlier, down by 72.1% YoY.

Key Points: 
  • Unaudited consolidated EBITDA dropped to EUR 2.833 million compared to EUR 10.142 million a year earlier, down by 72.1% YoY.
  • Amsterdam – 21 August 2023 – Photon Energy N.V. (WSE&PSE: PEN, FSX: A1T9KW) (the ‘Group’ or the ‘Company’) announced unaudited financial results as of and for the six months ended June 30, 2023, as well as recent operational developments.
  • The Group completed and grid-connected its first Romanian PV power plants with a total installed capacity of 22.1 MWp.
  • Current 2023 revenue expectations compared to 2022 consolidated revenues of EUR 95.1 million translate into a 15.6% increase YoY.